You are here
The why, the which, and the how of targeting angiogenesis in GI malignancies
Official Sponsored Satellite Symposium at European Cancer Congress 2015 - Monday 28 September 2015
Angiogenesis plays an important role in the progression of gastrointestinal (GI) malignancies. Anti-angiogenic treatments have improved the overall survival of patients with these cancers. The introduction of new anti-angiogenic agents warrants both exploration of the latest clinical data and discussion on how treatments involving anti-angiogenic drugs can be used to optimize outcomes in this patient group.
Learning objectives of the symposium:
- To understand the mechanisms and biology of angiogenesis in cancer
- To be aware of the latest clinical trials investigating angiogenesis-targeting therapies in GI malignancies
- To understand which therapies or treatment combinations produce optimal patient outcomes
- To understand which patients would benefit from the latest developments, and how to optimize their management in daily clinical practice
F. Lordick (Germany)
Florian Lordick introduces the symposium, about the mechanisms and biology of angiogenesis in cancer, highlighting the latest clinical trials of angiogenesis-targeting therapies in GI malignancies and investigating how patients can benefit from different treatments.
R. Danesi (Italy)
Romano Danesi talks about the morphology and mechanisms of angiogenesis and the drugs that target it. The presentation covers the role of VEGF – the most important mediator of angiogenesis.
The Which: Clinical Evidence and Ongoing Trials in Anti-Angiogenic Treatments - Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma
H. Wilke (Germany)
Hansjochen Wilke covers first-line chemotherapy for gastric and gastro-oesophageal junction adenocarcinoma. The presentation looks at significant clinical trials, their methodologies and results.
I. Chau (United Kingdom)
Ian Chau covers the challenges of treating colorectal cancer, looking at the molecular characterization and current systemic therapies. The presentation includes relevant clinical trials and considers different treatment paradigms.
The Which: Clinical Evidence and Ongoing Trials in Anti-Angiogenic Treatments - Hepatocellular Carcinoma
L. Bolondi (Italy)
Luigi Bolondi talks about liver cancer, introducing some of its characteristics, such as abnormal arterial vascularization. The presentation then considers phase III clinical trials and looks to the future of treatment beyond sorafenib.
The How: Selecting Eligible Patients and Optimising Their Outcomes in Daily Clinical Practice − Case-Based Discussion
The symposium’s speakers discuss case studies and consider what treatments physicians would recommend, looking at how outcomes could be optimized.